Double‐Blind Multiple‐Dose Crossover Study of the Antiemetic Effect of Intramuscular Levonantradol Compared to Prochlorperazine

VIVIAN R. SHEIDLER, DAVID S. ETTINGER, ROBERT B. DIASIO, JOHN P. ENTERLINE, MICHAEL D. BROWN

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Abstract: Twenty cancer patients who received chemotherapy were entered into a double‐blind crossover design antiemetic study comparing 1 mg levonantradol, an investigational synthetic cannabinoid, to 10 mg prochlorperazine. Sixteen patients completed the crossover. For each antiemetic course, four doses of each study medication were given intramuscularly 2 hours before chemotherapy and then 2,6, and 10 hours after chemotherapy administration. There were no statistical differences in patients' responses to levonantradol and prochlorperazine. The frequency of side effects was greater with levonantradol than with prochlorperazine. The most common side effect of levonantradol were somnolence, dry mouth, dizziness, tachycardia, postural hypotension, and blurred vision, while those for prochlorperazine were somnolence, dry mouth, and tachycardia. 1984 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)155-159
Number of pages5
JournalThe Journal of Clinical Pharmacology
Volume24
Issue number4
DOIs
StatePublished - Apr 1984

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Double‐Blind Multiple‐Dose Crossover Study of the Antiemetic Effect of Intramuscular Levonantradol Compared to Prochlorperazine'. Together they form a unique fingerprint.

  • Cite this